Genmab — Juni 2017

Darvin

Go morn og tak Bongo og gen med sidste nye

JKY_VH

tak bongo

bongobob

Her er lidt resultater fra Dara i AL: http://www.bloodjournal.org/content/early/2017/06/14/blood-2017-01-763599

bibob

Tak for nyhed Bongo. Det var opløftende.

bongobob

"Daratumumab is a highly effective agent that produced rapid and deep hematologic responses without unexpected toxicity in our cohort of heavily pretreated AL patients"

bongobob

Jeg synes vi har set det før

JKY_VH

bongobob

Der er gang i den i dag. GEN har taget et mege bredt patent på AXL. Det ser ud til de har fået det hele med fra inhibitor til diagnostic kit: http://www.freshpatents.com/-dt20170608ptan20170157250.php

bongobob

meget

E_L

On that patent, i see "PCT Filed: Jul. 10, 2015", so i am guessing it took 2 years to get patent approved...?

E_L

and only after approval they can start their clinical trials i imagine...

bongobob

Yes but you still have rights when "Patent pending". I don't think it is a show stopper

KWC

Nogen der har futures på Genmab ?

E_L

something else, the new clinical trial gentogen posted last night is great, but Waldenström is a rare disease, with only about 1,500 cases per year in the United States

GeorgeBest

LONDON, June 15 (Reuters) - Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis NOVN.S in a new $300 million fund run by leading life sciences investment firm Medicxi.
The move shows Google casting an increasingly wide net as it pumps cash into global medical research, seeding what it believes will become a core long-term healthcare business.
Novartis and Verily, a unit of Google parent Alphabet GOOGL.O

GeorgeBest

are cornerstone investors in the new fund, along with the European Investment Fund, Medicxi said on Thursday.
Verily already has deals with GlaxoSmithKline GSK.L, Sanofi SASY.PA, Novartis and Johnson & Johnson JNJ.N to apply novel technology in areas ranging from diabetes management to robotic surgery. Last month it landed former U.S. Food and Drug Administration head Robert Califf as part of its team.
Another Google offshoot, Calico, is working on treatments to fight ageing, while the group's

E_L

in the article I posted yesterday, it stated that the keytruda approval was the first time the FDA has approved a cancer treatment based on a common biomarker rather than the location in the body where the tu
mor originated

E_L

I wonder if this could be a potential future for Dara, to be approved as a broad/general CD38 antibody, to be used for various different cancers?

Sukkeralf

Jan kind og mentioned at the GS presentation that Janssen and partners probably would use biomarker selection of patients in solid tumors

Sukkeralf

Antallet af immunonkologistudier er eksploderet

På blot 18 måneder er antallet af igangværende studier med de banebrydende immunterapier rettet mod proteinparret PD-1 og PD-L1 blevet mere end tredoblet. Blandt andet er der nu en håndfuld studier i gang med midler fra danske biotekselskaber.

(medwatch.dk)